PulseAugur
LIVE 13:37:57
tool · [1 source] · · 中文(ZH) 圣晖集成:控股子公司中标约2.23亿元项目

Shenghui Integration subsidiary wins $22.3M Indonesian construction project

Shenghui Integration's Indonesian subsidiary has secured a significant construction project valued at approximately 223 million RMB. This project involves the development of a shoe sole and footwear production facility. Separately, a subsidiary of Sunshine Nuohe has received approval for clinical trials for its STC009 injection, intended for treating secondary hyperparathyroidism. AI

Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →

IMPACT This cluster reports on a construction project win and a drug trial approval, with no direct impact on AI operators.

RANK_REASON The cluster contains news about subsidiaries winning contracts and receiving regulatory approval for drug trials, which are not frontier AI releases or significant industry-wide events.

Read on 36氪 (36Kr) →

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Shenghui Integration: Subsidiary Wins Bid for Project Worth Approximately 223 Million Yuan

    36氪获悉,圣晖集成公告,公司控股子公司PT ACTER INTEGRATION TECHNOLOGY INDONESIA(简称“印尼合资公司”)于近日收到PT. Hardases Abadi Indonesia发来的通知,印尼合资公司中标“PT.HAI F12及F12-1胶底与鞋类生产厂房第二期建设案”,工程总价为5628亿印尼卢比(未税),约为人民币2.23亿元(未税)。